血府逐瘀胶囊对重度血瘀证患者经皮冠状动脉介入治疗术后氯吡格雷抵抗的调节作用
投稿时间:2018-04-08  修订日期:2018-07-03  点此下载全文
引用本文:黄瑾,李璐奕,祁炜罡,黄瑛,曾颖,唐帆.血府逐瘀胶囊对重度血瘀证患者经皮冠状动脉介入治疗术后氯吡格雷抵抗的调节作用[J].药学实践杂志,2018,36(6):533~535,546
摘要点击次数: 64
全文下载次数: 75
作者单位
黄瑾 上海中医药大学附属岳阳中西医结合医院药学部, 上海 200437
上海市浦东新区人民医院药剂科, 上海 201299 
李璐奕 上海市浦东新区人民医院药剂科, 上海 201299 
祁炜罡 上海市浦东新区人民医院心内科, 上海 201299 
黄瑛 上海市浦东新区人民医院心内科, 上海 201299 
曾颖 上海市浦东新区人民医院药剂科, 上海 201299 
唐帆 上海市浦东新区人民医院药剂科, 上海 201299 
基金项目:浦东新区卫生系统学科带头人培养计划(PWRd-2014-11);浦东新区示范中药药剂学科(示范中药房)建设项目(PDZYXK-2-2013003)
中文摘要:目的 观察血府逐瘀胶囊联合氯吡格雷治疗氯吡格雷抵抗患者的效果,评价其改善氯吡格雷抵抗作用的效果。方法 经皮冠状动脉介入治疗(PCI)术后氯吡格雷抵抗患者80人,随机分组,分别给予3种药物治疗方案:A组用国产氯吡格雷(泰嘉)加用血府逐瘀胶囊;B组使用进口氯吡格雷(波立维);C组用国产氯吡格雷(泰嘉)加用西洛他唑,连续3个月,采用血栓弹力图法检测干预后血小板抑制率。并随访患者半年,观察临床不良事件的发生率。结果 治疗3个月后,各组抑制率均有所提高,且均有显著差异(P<0.05)。A组对血小板抑制的有效率达40%,优于C组(33.33%),与B组相当(40.74%)。对阿司匹林、氯吡格雷均不敏感的患者换用进口波立维对提高血小板抑制效果更佳;仅对氯吡格雷不敏感的患者加用血府逐瘀胶囊对血小板抑制有协同作用。随访半年后发现,联合使用血府逐瘀胶囊的时间延长可能会增强血小板抑制的效果,但并不增加出血及凝血功能异常等风险。结论 血府逐瘀胶囊对提高血小板抑制率有一定的作用,同时对出血风险影响较小。
中文关键词:血府逐瘀胶囊  血瘀证  氯吡格雷抵抗  冠状动脉粥样硬化
 
Regulating effect of Xuefuzhuyu capsule on clopidogrel resistance in patients with severe blood stasis syndrome after PCI operation
Abstract:Objective To observe and evaluate the regulating effect of Xuefuzhuyu capsule combined with clopidogrel on clopidogrel resistance. Methods After PCI operation, 80 patients with clopidogrel resistance were randomly divided into three different treatments,A:clopidogrel (Tai Jia) combined with Xuefuzhuyu capsule; B:clopidogrel (Plavix); C:clopidogrel (Tai Jia) combined with cilostazol.)After three months of continuous medication, and the inhibition rate of platelet aggregation was detected by thromboela-stogram(TEG).The patients were followed up for half a year to observe the incidence of adverse events.Results After three months of treatment, the inhibition rates of the three groups were improved(P<0.05).The effective rate of platelet inhibition in group A was 40% (10/25), which was higher to group C (33.33%), and which was equivalent to group B (40.74%). The effect of platelet aggregation inhibition was better in patients who were not sensitive to aspirin and clopidogrel and then with imported Plavix. And the treatment group of clopidogrel combined with Xuefuzhuyu capsule had a synergistic effect on platelet aggregation inhibition for clopidogrel insensitive patients. After six months' follow-up, it was found that the platelet inhibition was enhanced but the bleeding risk and abnormal coagulation function was not increased after prolonged using of Xuefuzhuyu capsule.Conclusion Xuefuzhuyu capsule had a certain effect on improving the inhibition rate of platelet aggregation, which had little effect on the risk of bleeding.
keywords:Xuefuzhuyu capsule  blood stasis syndrome  clopidogrel resistance  coronary atherosclerosis
查看全文  查看/发表评论  下载PDF阅读器
关闭

分享按钮